E-Z-EM's PercuPump CT Injector Rated Highest in Industry by MDB Information Network

Only Contrast Injector Capable of Detecting Extravasation Receives Highest Analyst
                  Quality Ratings for Second Year in a Row

WESTBURY, N.Y. Dec. 13, 2000 E-Z-EM, Inc. (AMEX - EZM.A and EZM.B) today announced that its
PercuPump® CT injector with patented EDA(TM) technology has been awarded top quality ratings in
the CT power injection market for the second year in a row. The ratings were published by MDB
Information Network, provider of the world's largest medical and information technology database.
The PercuPump® EDA(TM) injector, the only CT injector that can help detect contrast media
extravasation, ranked number one in Analyst Quality Ratings and received a score of 9.5 out of a
maximum score of 10. 

Commenting on the announcement, Joseph J. Palma, Senior Vice President of Sales and Marketing at
E-Z-EM, said, ``We are very proud to be again rated first by analysts for MDB Information Network,
which is looked upon as the primary source for current, accurate information on medical equipment
and healthcare information systems. To be rated above the major industry leaders in CT power
injectors is a testimonial to the value of the patented extravasation technology built into our
injectors. Our PercuPump® with EDA(TM) (Extravasation Detection Accessory) is helping to prevent 
potentially serious medical complications in hospitals and imaging centers, to say nothing of the
legal and financial implications of an extravasation.'' 

Extravasation can occur whenever diagnostic or therapeutic agents - such as ionic and non-ionic
contrast agents, chemotherapeutic agents, or IV fluids - are administered intravenously. While 
articles have shown that from 0.04% to 1.3% of the 10 million contrast procedures performed
annually in the United States result in an extravasation, the absolute number is substantial 
because the base number of procedures is so large. EDA(TM) technology is able to help detect 
extravasations before they become clinically significant, greatly minimizing the risk of severe 
skin and subcutaneous tissue damage and the potential need for skin grafts or plastic surgery.

Begun in 1983, MDB Information Network has over 2,500 member facilities in the healthcare
industry. Data for comparative analysis of medical technology, which is gathered globally from
these members, from clinical sites and from 1,800 equipment vendors, is used by members to aid 
in making informed purchasing decisions. The Quality Ratings published by MDB are divided into 
Analyst Quality Ratings and User Quality Ratings. Analyst Ratings are based on a combination of 
factors evaluated by MDB's clinical and corporate analysts, including Corporate, Product and 
Service factors which may involve visits with the vendor, discussions with customers and relative
assessment of how the vendor compares with the competition and other industry benchmark 
companies. Topics such as Innovation, Value, Product Performance, Commitment to Customer and 
Industry are evaluated. User Ratings are compiled from interviews with healthcare providers, and 
include ratings on Service, Performance, Reliability, Vendor Relationship, Training, Pre- and
Post-Purchase Experience and Upgradeability. The PercuPump® with EDA(TM) received a User Quality 
Rating of 9.1 by MDB for 2000. 

E-Z-EM, Inc. is the world's largest manufacturer of diagnostic contrast agents and related 
imaging accessories for gastrointestinal radiology. The Company's wholly-owned subsidiary,
AngioDynamics, Inc., manufactures a wide range of products, including angiographic, thrombolytic,
vascular access, and drainage products, as well as stents and medical devices for angioplasty. 
Another subsidiary, Enteric Products, Inc., develops, manufactures and markets tests for 
detection of the ulcer-causing bacterium Helicobacter pylori. For additional information, please
contact Frank Kerrigon at 1-800-544-4624, ext. 325, (E-mail: fkerrigon@ezem.com) or visit our
corporate web site at www.ezem.com. 

The statements made in this document contain certain forward-looking statements that involve a 
number of risks and uncertainties. Words such as ``expects'', ``intends'', ``anticipates'',
``plans'', ``believes'', ``seeks'', ``estimates'', or variations of such words and similar 
expressions, are intended to identify such forward-looking statements. Investors are cautioned 
that actual events or results may differ from the Company's expectations. In addition to the 
matters described above, the ability of the Company to develop its products, future actions by
the FDA or other regulatory agencies, results of pending or future clinical trials, general 
market conditions, competition and pricing, as well as the risk factors listed from time to time 
in the SEC filings of E-Z-EM, Inc., including but not limited to its Annual Report on Form 10-K 
for the year ended June 3, 2000, may affect the actual results achieved by the Company. 

Contact: 

     E-Z-EM, Inc., Westbury
     Tom McLaughlin, 800/544-4624, ext. 504
     tmclaughlin@ezem.com

End